Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:25 PM
Ignite Modification Date:
2025-12-24 @ 9:25 PM
NCT ID:
NCT06443632
Eligibility Criteria:
Inclusion Criteria:
* Patient of any gender, aged 0-4 years
* Pathologically confirmed diagnosis of pediatric malignant solid tumors (including Wilms tumor, neuroblastoma, rhabdomyosarcoma, hepatoblastoma, germ cell tumors, etc.).
* The child's parents can cooperate with the implementation of the sleep training plan.
* Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
* Expected survival of the patient ≥3 months.
* Normal major organ function (within 14 days before enrollment)
* Growth and immune function are within acceptable ranges as determined by the investigator.
* The patient's parents must provide informed consent for the study before participation and voluntarily sign the informed consent form.
Exclusion Criteria:
* Primary or metastatic lesions that cannot undergo radiotherapy (as determined by the investigator).
* Children who can independently maintain position fixation.
* Children with clinical signs of central nervous system dysfunction.
* Children with sleep disorders.
* Children with severe growth retardation or immune function impairment.
* Other significant medical conditions that may impact the study (e.g., severe cardiopulmonary diseases). The decision is at the discretion of the investigator.
* Severe or uncontrolled infections.
* Allergy to sedatives.
* The investigator deems the patient unsuitable for participation in this clinical study for other reasons.
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
4 Years
Study:
NCT06443632
Study Brief:
Protocol Section:
NCT06443632